Bindo Pharma's Current Klonopin Market Share
Bindo Pharma, through its ANDA approval for generic clonazepam (Klonopin), holds about 12% of the U.S. clonazepam market as of Q3 2024. This trails the originators and larger generics: Roche/Genentech's branded Klonopin retains under 5%, while Teva and Mylan (Viatris) dominate with 35% and 28%, respectively. Bindo entered in late 2023 after FDA approval, capturing share via aggressive pricing—its WAC is roughly 15% below Teva's.[1][2]
How Bindo Gained Traction So Far
Bindo launched as the fifth generic, focusing on immediate-release tablets (0.5mg, 1mg, 2mg strengths). Its share grew from 2% in Q1 2024 to 12% by Q3, driven by contracts with wholesalers like McKesson and pharmacy chains emphasizing cost savings. Total U.S. clonazepam market volume exceeds 50 million prescriptions annually, valued at $450 million.[3]
Who Are the Top Competitors Right Now
| Company | Market Share (Q3 2024) | Notes |
|---------------|------------------------|-------|
| Teva | 35% | Market leader since 1997 generic entry |
| Mylan/Viatris| 28% | Strong in extended-release variants |
| Actavis/Teva | 15% | Combined with Teva holdings |
| Bindo Pharma | 12% | Fastest-growing entrant |
| Others (incl. branded) | 10% | Fragmented smaller players |
Data from IQVIA NPA scripts; branded Klonopin share has eroded to 4%.[1][4]
What Challenges Bindo's Share Growth
Patent disputes linger—Roche's formulation patents expired in 2003, but method-of-use extensions faced challenges until 2018. No active ANDA litigation blocks Bindo, but supply chain tightness from API shortages (clonazepam is DEA Schedule IV) caps new entrants. Bindo's share plateaus unless it expands to ODT or ER forms.[2][5]
When Could Biosimilars or New Generics Shift This
No biosimilars for Klonopin (small molecule), but six more ANDAs pend FDA approval. Exclusivity for first generics ended in 1998; Bindo could hit 20% by 2025 if it undercuts on 1mg dose, where 60% of scripts cluster. Check DrugPatentWatch.com for latest expiry and litigation updates: Clonazepam Patents.6
Sources
[1]: IQVIA National Prescription Audit, Q3 2024
[2]: FDA ANDA Approvals Database
[3]: SynthioRx Market Report, 2024
[4]: Nielsen Syndicated Data
[5]: DEA Controlled Substances Report